Stocks · News reference

Armata Pharmaceuticals Announces Two U.S. Patents Covering AP-SA02 And AP-PA02 Phage Therapies, With Protection Until At Least 2041

Oct 7, 2026, 11:10 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 23, 2026, 4:58 PMBenzinga Newsdesk
Armata Pharmaceuticals shares are trading lower after the company announced the receipt of an additional $3.7 million in non-dilutive funds from the U.S. DoW for Phase 3 development program for AP-SA02.
ARMP
BenzingaSep 23, 2026, 4:12 PMVandana Singh
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program
Armata Pharmaceuticals technical headwinds overshadow a $3.7 million Department of Defense grant funding its Phase 3 bacteriophage program.
ARMP
BenzingaSep 23, 2026, 2:54 PMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $15 price target.
ARMP